Ocular Therapeutics (OCUL) 09/06/2016 www.ocutx.com Pipeline: Focus mainly on developing therapies for diseases and conditions of the eye. Product Indication Status Resure Sealant Cataract incision closure Regulatory approval Dextenza (sustained release dexamethasone depot) Post-surgical pain and inflammation Late Phase 3 Dextenza (sustained release dexamethasone depot) Allergic Conjunctivitis Phase 3 OTX-TP (Sustained release Travoprost) Glaucoma Phase 3 Dextenza (sustained release dexamethasone
www.ocutx.com Pipeline: Focus mainly on developing therapies for diseases and conditions of the eye. Product Indication Status Resure Sealant Cataract incision closure Regulatory approval Dextenza (sustained release dexamethasone depot) Post-surgical pain and inflammation Late Phase 3 Dextenza (sustained release dexamethasone depot) Allergic Conjunctivitis Phase 3 OTX-TP (Sustained release Travoprost) Glaucoma Phase 3 Dextenza (sustained release dexamethasone
